# Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

> **NCT06434090** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 74 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Liposomal irinotecan
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06434090
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2025-06-05
- **Final completion:** 2026-07-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434090, "Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06434090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*